Freitas, Egídio
Blauvelt, Andrew http://orcid.org/0000-0002-2633-985X
Torres, Tiago http://orcid.org/0000-0003-0404-0870
Article History
Accepted: 19 September 2021
First Online: 8 October 2021
Declarations
:
: No funding was received for the preparation of this article.
: Egídio Freitas has no conflicts of interest. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, and Sandoz.
: EF, AB, and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.